The new drug has people who lose 60 pounds on average, shows research - and it's not ozempic
The study involved hundreds of patients, many have seen spectacular results.
New drug drugs and weight loss on the market have helped change the lives of many who seek to lose weight. Ozempic And Wegovy (semaglutide), both made by Novo Nordisk, are two of the most famous names, but they are not the only ones available. Mounjaro (shooting), another treatment currently approved for type 2 diabetes, is an option made by Eli Lilly and the company - and a new study has revealed that it can have spectacular results. Read the rest to find out how the medication helped patients lose 60 pounds on average.
In relation: The ozempic patient reveals "a new" atrocious "side effect .
The study evaluated its effectiveness for weight loss.
In a October 15 Press release , Eli Lilly announced the results of the 3 surmount-3 clinical trial, which studied the use of Mounjaro in patients with obesity and those who were overweight with weight-related comorbidities. Although the medication is currently approved for diabetes, the trial excluded these patients and focused on out -of -the -line uses for weight loss.
According to the results of the study published in Nature Medicine , patients were divided into two groups , one receiving Mounjaro and another receiving a placebo injection, for 16 months. The study started with 800 patients, but after a three -month "entry period" - which involved diet, exercise and advice - more than 200 people have abandoned for a range of reasons ( in particular not to lose enough weight).
In relation: Ozempic patients report a new debilitating side effect: "I want me to never touched it."
Those of Mounjaro have seen better weight loss results.
When the study started, patients weighed an average of 241 pounds and at the end of the 12 -week diet and exercise period, participants fell on average 16.8 pounds, around 7%. During the period that followed, those of Mounjaro lost 21% of their body weight.
In total, from the entry of the study to 84 weeks completion, Mounjaro patients lost a total of 26.6% of their body weight, which was equivalent to 64.4 pounds. Those who take the placebo have lost only 3.8% of their body weight, or nine pounds, from start to finish.
"In this study, people who added shooting to diet and exercise experienced a longer and more durable weight reduction than those who take a placebo" " Jeff Emmick , MD, PHD, Vice-President Director of Product Development at Eli Lilly, in the press release. "Although the intensive intervention of the lifestyle is an important part of the management of obesity, these results underline the difficulty with which some people face to maintain weight loss with a diet and the exercise alone . " AE0FCC31AE342FD3A1346EBB1F342FCB
In relation: 4 foods that increase the same weight loss hormone as Ozempic, experts say .
The results were also better than those observed with the semaglutide.
About 88% of people taking Mounjaro also lost 5% or more of their body weight during the study, against only 17% of those who take the placebo. In addition, 29% of people receiving treatment lost a huge quarter of their body weight - compared to only 1% of patients in the placebo group.
As Caroline Apovian , MD, a doctor who treats obesity in Brigham and Women's Hospital in Boston, told the Associated Press (AP), these The figures are better that those observed for semaglutide and comparable to the results obtained by surgery.
"We do a medical gastric puncture," said Apovian, who was not involved in the study, adding: "Anyway, you cut it, it's a quarter of your total body weight."
According to AP, like Ozempic, Mounjaro is currently prescribed out of AMM for the treatment of obesity. However, it is different from Ozempic and Wegovy because it targets two hormones to regulate appetite and the feeling of being "full". The other two drugs target only one hormone.
In relation: FDA problems .
There have been side effects.
As for most drugs, some side effects have been reported in the Mounjaro study. The most commonly reported problems were linked to gastrointestinal, ranging from light to moderate gravity.
Patients from the two groups reported nausea, diarrhea, constipation and vomiting and COVID-19. More Moujaro patients reported gastrointestinal problems, while a little more people taking the placebo said COVVI-19. These undesirable events led 10.5% of patients who took Mounjaro to abandon the study, against 2.1% of those who take the placebo.
Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.
In relation: For more information, register for our daily newsletter .
The most optimistic zodiac sign, according to astrologers
